Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navicixizumab +/- Paclitaxel vs Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT05043402Phase 3Unknown
- Sponsor
- OncXerna Therapeutics
- Start
- Nov 2022
- Primary completion
- Nov 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 3 trial of navicixizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by OncXerna Therapeutics. Status: unknown.
02
Drugs
navicixizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT05043402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043402.